

# Dipen J Parekh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10736260/publications.pdf>

Version: 2024-02-01

120  
papers

4,561  
citations

116194

36  
h-index

120465

65  
g-index

123  
all docs

123  
docs citations

123  
times ranked

5319  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anterior or Posterior Prostate Cancer Tumor Nodule Location Predicts Likelihood of Certain Adverse Outcomes at Radical Prostatectomy. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 833-839.	1.2	2
2	Prostatic Ductal Adenocarcinoma Controlled for Tumor Grade, Stage, and Margin Status Does Not Independently Influence the Likelihood of Biochemical Recurrence in Localized Prostate Cancer After Radical Prostatectomy. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 1012-1017.	1.2	6
3	Predictive Value of Sequential Organ Failure Assessment Score across Patients with and without COVID-19 Infection. <i>Annals of the American Thoracic Society</i> , 2022, 19, 790-798.	1.5	6
4	Association of care by a non-medical intensive care unit provider team with outcomes of medically critically ill patients. <i>Journal of Critical Care</i> , 2022, 68, 129-135.	1.0	0
5	Real world SARS-COV-2 vaccine effectiveness in a Miami academic institution. <i>American Journal of Emergency Medicine</i> , 2022, 54, 97-101.	0.7	6
6	Editorial: Impact of coronavirus disease 2019 on urological healthcare. <i>Current Opinion in Urology</i> , 2022, 32, 123.	0.9	0
7	Comparison of Robot-Assisted and Open Radical Cystectomy in Recovery of Patient-Reported and Performance-Related Measures of Independence. <i>JAMA Network Open</i> , 2022, 5, e2148329.	2.8	12
8	Focal therapy for localized prostate cancer – Current status. <i>Indian Journal of Urology</i> , 2022, 38, 7.	0.2	0
9	Prostate cancer upgrading and adverse pathology in Hispanic men undergoing radical prostatectomy. <i>World Journal of Urology</i> , 2022, 40, 2017-2023.	1.2	1
10	A 4Kscore Cut-off of 7.5% for Prostate Biopsy Decisions Provides High Sensitivity and Negative Predictive Value for Significant Prostate Cancer. <i>Urology</i> , 2021, 148, 53-58.	0.5	6
11	Androgen Suppression Therapy Is Associated with Lower Recurrence of Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2021, 7, 142-147.	1.6	14
12	Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. <i>Journal of Urology</i> , 2021, 205, 1344-1351.	0.2	5
13	Application of the ACMG / NSGC genetic referral guidelines for hereditary renal cell carcinoma at the University of Miami, from 2014 to 2017. <i>American Journal of Medical Genetics, Part A</i> , 2021, 185, 3012-3018.	0.7	0
14	Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers. <i>Prostate</i> , 2021, 81, 866-873.	1.2	3
15	Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 27-28.	0.2	0
16	Surveillance Intensity in Intermediate Risk, Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy. <i>Journal of Urology</i> , 2021, 206, 22-28.	0.2	6
17	Impact of Plant-Based Diet on PSA Level: Data From the National Health and Nutrition Examination Survey. <i>Urology</i> , 2021, 156, 205-210.	0.5	10
18	Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer: a propensity matched analysis. <i>Minerva Urology and Nephrology</i> , 2021, 73, 572-580.	1.3	7

#	ARTICLE	IF	CITATIONS
19	Variance of Tumor Grade at Radical Prostatectomy With Assessment of Each Tumor Nodule Versus Global Grading. Archives of Pathology and Laboratory Medicine, 2021, , .	1.2	1
20	Timing of adjuvant chemotherapy and overall survival following radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 75.e15-75.e22.	0.8	9
21	Focal therapy for localized prostate cancer: Where do we stand?. European Urology Focus, 2020, 6, 208-211.	1.6	6
22	Prostatic Ductal Adenocarcinoma Controlled for Cancer Grade and Tumor Volume Does Not Have an Independent Effect on Adverse Radical Prostatectomy Outcomes Compared to Usual Acinar Prostatic Adenocarcinoma. Urology, 2020, 137, 108-114.	0.5	11
23	Performance of Multiparametric MRI of the Prostate in Biopsy Naïve Men: A Meta-analysis of Prospective Studies. Urology, 2020, 146, 189-195.	0.5	9
24	A How-to Guide to Building a Robust SARS-CoV-2 Testing Program at a University-Based Health System. Academic Pathology, 2020, 7, 2374289520958200.	0.7	4
25	Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. European Urology, 2020, 78, 489-491.	0.9	8
26	Predicting intraoperative and postoperative consequential events using machine learning techniques in patients undergoing robot-assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study. BJU International, 2020, 126, 350-358.	1.3	14
27	Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. Journal of Urology, 2020, 203, 522-529.	0.2	75
28	Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort. Journal of Urology, 2020, 203, 505-511.	0.2	63
29	The Balance between Open and Robotic Training among Graduating Urology Residents—Does Surgical Technique Need Monitoring?. Journal of Urology, 2020, 203, 996-1002.	0.2	9
30	Prospective Evaluation of Focal High Intensity Focused Ultrasound for Localized Prostate Cancer. Journal of Urology, 2020, 204, 483-489.	0.2	18
31	Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy. Journal of Urology, 2020, 204, 450-459.	0.2	26
32	Reply by Authors. Journal of Urology, 2020, 203, 511-511.	0.2	0
33	Does Every Minute of Renal Ischemia Still Count in 2019? Unlocking the Chains of a Flawed Thought Process over Five Decades. European Urology Focus, 2019, 5, 939-942.	1.6	18
34	Propensity-matched analysis of stage-specific efficacy of adjuvant chemotherapy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 877-885.	0.8	3
35	Impact of Surgical Technique on Surgical Margin Status Following Partial Cystectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 870-876.	0.8	6
36	Metastatic Renal Cell Carcinoma with Level IV Thrombus: Contemporary Management with Complete Response to Neoadjuvant Targeted Therapy. Case Reports in Urology, 2019, 2019, 1-5.	0.1	9

#	ARTICLE	IF	CITATIONS
37	Evidence trumps consensus. BJU International, 2019, 123, 374-375.	1.3	1
38	Robot-assisted versus open cystectomy in the RAZOR trial – Authors' reply. Lancet, The, 2019, 393, 645-646.	6.3	1
39	<i>Editorial Comment on: Does the Use of the Robot Decrease the Complication Rate Adherent to Radical Cystectomy? A Systematic Review and Meta-Analysis of Studies Comparing Open to Robotic Counterparts by Tzelves et al. (From: Tzelves L, Skolarikos A, Mourmouris P, et al. J Endourol) Tj ETQq1 1 0.784314 11 BT /Overflock 10</i>	1.1	0
40	Trends in Utilization of Robotic and Open Partial Nephrectomy for Management of cT1 Renal Masses. European Urology Focus, 2019, 5, 482-487.	1.6	42
41	The Influence of Ethnic Heterogeneity on Prostate Cancer Mortality After Radical Prostatectomy in Hispanic or Latino Men: A Population-based Analysis. Urology, 2018, 117, 108-114.	0.5	12
42	Malakoplakia of the prostate diagnosed on multiparametric-MRI ultrasound fusion guided biopsy: A case report and review of the literature. Urology Case Reports, 2018, 18, 94-96.	0.1	3
43	Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies. Journal of Urology, 2018, 199, 1488-1493.	0.2	18
44	Editorial Comment. Journal of Urology, 2018, 199, 138-138.	0.2	0
45	Comparison of readmission and short-term mortality rates between different types of urinary diversion in patients undergoing radical cystectomy. World Journal of Urology, 2018, 36, 393-399.	1.2	11
46	Efficacy of Prostatic Artery Embolization for Catheter-Dependent Patients with Large Prostate Sizes and High Comorbidity Scores. Journal of Vascular and Interventional Radiology, 2018, 29, 78-84.e1.	0.2	39
47	Entering an era of radiogenomics in prostate cancer risk stratification. Translational Andrology and Urology, 2018, 7, S443-S452.	0.6	7
48	Robot-Assisted Radical Cystectomy Versus Open Radical Cystectomy. , 2018, , 797-808.		0
49	Prostate Artery Embolization in Patients with Prostate Volumes of 80 mL or More: A Single-Institution Retrospective Experience of 93 Patients. Journal of Vascular and Interventional Radiology, 2018, 29, 1392-1398.	0.2	42
50	Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet, The, 2018, 391, 2525-2536.	6.3	537
51	Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study. Prostate Cancer and Prostatic Diseases, 2018, 21, 533-538.	2.0	13
52	Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer. PLoS ONE, 2018, 13, e0201384.	1.1	37
53	Lymph node yield as a predictor of overall survival following inguinal lymphadenectomy for penile cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 471.e19-471.e27.	0.8	20
54	The 4Kscore Predicts the Grade and Stage of Prostate Cancer in the Radical Prostatectomy Specimen: Results from a Multi-institutional Prospective Trial. European Urology Focus, 2017, 3, 94-99.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Current Status of Nephron-Sparing Surgery (NSS) in the Management of Renal Tumours. Indian Journal of Surgical Oncology, 2017, 8, 150-155.	0.3	7
56	Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy. Urology, 2017, 105, 123-128.	0.5	59
57	Partial Gland Treatment of Prostate Cancer Using High-Intensity Focused Ultrasound in the Primary and Salvage Settings: A Systematic Review. Journal of Urology, 2017, 198, 1000-1009.	0.2	38
58	Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer. Journal of Urology, 2017, 198, 266-267.	0.2	0
59	Outcomes of Laparoscopic and Robotic Partial Nephrectomy for Large (>4ÅCm) Kidney Tumors: Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2017, 24, 2420-2428.	0.7	18
60	Reclassification Rates of Patients Eligible for Active Surveillance After the Addition of Magnetic Resonance Imaging-Ultrasound Fusion Biopsy: An Analysis of 7 Widely Used Eligibility Criteria. Urology, 2017, 110, 134-139.	0.5	9
61	Predictive models and risk of biopsy progression in active surveillance patients. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 37.e1-37.e8.	0.8	4
62	Robotic Partial Nephrectomy with the Da Vinci Xi. Advances in Urology, 2016, 2016, 1-5.	0.6	19
63	Long-term response to renal ischaemia in the human kidney after partial nephrectomy: results from a prospective clinical trial. BJU International, 2016, 117, 766-774.	1.3	32
64	Prediagnostic prostate-specific antigen kinetics and the risk of biopsy progression in active surveillance patients. International Journal of Urology, 2016, 23, 313-317.	0.5	3
65	Editorial Comment. Journal of Urology, 2016, 195, 1375-1375.	0.2	0
66	Is It Time to Revisit the Role of Prostate-specific Antigen Kinetics in Active Surveillance for Prostate Cancer?. Urology, 2016, 95, 139-144.	0.5	10
67	Current Paradigm for Ischemia in Kidney Surgery. Journal of Urology, 2016, 195, 1655-1663.	0.2	60
68	Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget, 2016, 7, 53362-53376.	0.8	90
69	A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. European Urology, 2015, 68, 464-470.	0.9	320
70	Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active Surveillance. Frontiers in Oncology, 2015, 5, 4.	1.3	8
71	The <sc>RAZOR</sc> (randomized open vs robotic cystectomy) trial: study design and trial update. BJU International, 2015, 115, 198-205.	1.3	73
72	Operative technique and early experience for robotic-assisted laparoscopic nephroureterectomy (RALNU) using da Vinci Xi. SpringerPlus, 2015, 4, 298.	1.2	25

#	ARTICLE	IF	CITATIONS
73	Average Weight of Seminal Vesicles. <i>International Journal of Surgical Pathology</i> , 2015, 23, 617-622.	0.4	15
74	Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise. <i>Indian Journal of Urology</i> , 2015, 31, 273.	0.2	19
75	Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. <i>Reviews in Urology</i> , 2015, 17, 3-13.	0.9	45
76	The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. <i>Reviews in Urology</i> , 2015, 17, 231-40.	0.9	31
77	Health-related quality of life from a prospective randomised clinical trial of robot-assisted laparoscopic vs open radical cystectomy. <i>BJU International</i> , 2014, 114, 896-902.	1.3	81
78	Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2014, 32, 185-191.	1.2	28
79	Definition, Incidence, Risk Factors, and Prevention of Paralytic Ileus Following Radical Cystectomy: A Systematic Review. <i>European Urology</i> , 2013, 64, 588-597.	0.9	88
80	Perioperative Outcomes and Oncologic Efficacy from a Pilot Prospective Randomized Clinical Trial of Open Versus Robotic Assisted Radical Cystectomy. <i>Journal of Urology</i> , 2013, 189, 474-479.	0.2	248
81	Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis. <i>BJU International</i> , 2013, 111, 1054-1060.	1.3	38
82	Tolerance of the Human Kidney to Isolated Controlled Ischemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 506-517.	3.0	178
83	Prostate Cancer Screening: Navigating the Controversy. , 2013, , 11-26.		1
84	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2012, 30, 181-187.	1.2	66
85	Nox4 Mediates Renal Cell Carcinoma Cell Invasion through Hypoxia-Induced Interleukin 6- and 8-Production. <i>PLoS ONE</i> , 2012, 7, e30712.	1.1	88
86	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2012, 30, 149-155.	1.2	101
87	Methods to Predict and Lower the Risk of Prostate Cancer. <i>Scientific World Journal</i> , The, 2011, 11, 742-748.	0.8	2
88	Reduced Expression of Fumarate Hydratase in Clear Cell Renal Cancer Mediates HIF-2 $\alpha$ Accumulation and Promotes Migration and Invasion. <i>PLoS ONE</i> , 2011, 6, e21037.	1.1	45
89	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010, 16, 4374-4381.	3.2	86
90	Prostate Cancer Prevention with 5 Alpha-Reductase Inhibitors. <i>Recent Results in Cancer Research</i> , 2010, 188, 109-114.	1.8	3

#	ARTICLE	IF	CITATIONS
91	Biomarkers for prostate cancer detection. Expert Review of Anticancer Therapy, 2010, 10, 103-114.	1.1	36
92	The NADPH Oxidase Subunit p22 Inhibits the Function of the Tumor Suppressor Protein Tuberin. American Journal of Pathology, 2010, 176, 2447-2455.	1.9	40
93	Yearly Prostate Specific Antigen and Digital Rectal Examination Fluctuations in a Screened Population. Journal of Urology, 2009, 181, 2071-2076.	0.2	19
94	Beware the Risks. Journal of Urology, 2009, 182, 2566-2568.	0.2	1
95	Integration of Risk Assessment in Prostate Cancer Screening. , 2009, , 205-211.		0
96	Assessment of 54 Biomarkers for Biopsy-Detectable Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1966-1972.	1.1	25
97	Biomarkers for Prostate Cancer Detection. Journal of Urology, 2007, 178, 2252-2259.	0.2	75
98	Current Age and Race Adjusted Prostate Specific Antigen Threshold Values Delay Diagnosis of High Grade Prostate Cancer. Journal of Urology, 2007, 178, 1929-1932.	0.2	26
99	Urinary Diversion: Options, Patient Selection, and Outcomes. Seminars in Oncology, 2007, 34, 98-109.	0.8	43
100	In Vivo Assessment of Radio Frequency Induced Thermal Damage of Kidney Using Optical Spectroscopy. Journal of Urology, 2006, 176, 1626-1630.	0.2	14
101	Superficial and Muscle-Invasive Bladder Cancer: Principles of Management for Outcomes Assessments. Journal of Clinical Oncology, 2006, 24, 5519-5527.	0.8	88
102	External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology, 2006, 68, 1152-1155.	0.5	104
103	RENAL CELL CARCINOMA WITH RENAL VEIN AND INFERIOR VENA CAVAL INVOLVEMENT: CLINICOPATHOLOGICAL FEATURES, SURGICAL TECHNIQUES AND OUTCOMES. Journal of Urology, 2005, 173, 1897-1902.	0.2	128
104	OPTICAL SPECTROSCOPY CHARACTERISTICS CAN DIFFERENTIATE BENIGN AND MALIGNANT RENAL TISSUES: A POTENTIALLY USEFUL MODALITY. Journal of Urology, 2005, 174, 1754-1758.	0.2	38
105	Complications of Radical Cystectomy For Nonmuscle Invasive Disease: Comparison With Muscle Invasive Disease. Journal of Urology, 2003, 169, 101-104.	0.2	119
106	Randomized Prospective Evaluation of Extended Versus Limited Lymph Node Dissection in Patients With Clinically Localized Prostate Cancer. Journal of Urology, 2003, 169, 145-148.	0.2	245
107	Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. Journal of Urology, 2003, 169, 101-4.	0.2	35
108	Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. Urology, 2002, 60, 164.	0.5	50

#	ARTICLE	IF	CITATIONS
109	Primary neuroendocrine carcinoma of the urethra. <i>Urology</i> , 2002, 60, 1111.	0.5	9
110	Orthotopic Neobladder Following Radical Cystectomy in Patients with High Perioperative Risk and Co-morbid Medical Conditions. <i>Journal of Urology</i> , 2002, 168, 2454-2456.	0.2	37
111	OUTCOME OF SIBLING VESICoureTERAL REFLUX. <i>Journal of Urology</i> , 2002, 167, 283-284.	0.2	38
112	THE ASSOCIATION OF AN INCREASED URINARY CALCIUM-TO- CREATININE RATIO, AND ASYMPTOMATIC GROSS AND MICROSCOPIC HEMATURIA IN CHILDREN. <i>Journal of Urology</i> , 2002, 167, 272-274.	0.2	25
113	Orthotopic Neobladder Following Radical Cystectomy in Patients with High Perioperative Risk and Co-morbid Medical Conditions. <i>Journal of Urology</i> , 2002, , 2454-2456.	0.2	0
114	The association of an increased urinary calcium-to-creatinine ratio, and asymptomatic gross and microscopic hematuria in children. <i>Journal of Urology</i> , 2002, 167, 272-4.	0.2	5
115	Outcome of sibling vesicoureteral reflux. <i>Journal of Urology</i> , 2002, 167, 283-4.	0.2	12
116	Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and co-morbid medical conditions. <i>Journal of Urology</i> , 2002, 168, 2454-6.	0.2	22
117	HEALTH RELATED QUALITY OF LIFE ASSESSMENT AFTER RADICAL PROSTATECTOMY IN MEN WITH PROSTATE SPECIFIC ANTIGEN ONLY RECURRENCE. <i>Journal of Urology</i> , 2001, 166, 2286-2290.	0.2	30
118	THE USE OF RADIOGRAPHY, URODYNAMIC STUDIES AND CYSTOSCOPY IN THE EVALUATION OF VOIDING DYSFUNCTION. <i>Journal of Urology</i> , 2001, 165, 215-218.	0.2	49
119	Continent urinary reconstruction versus ileal conduit: a contemporary single-institution comparison of perioperative morbidity and mortality. <i>Urology</i> , 2000, 55, 852-855.	0.5	94
120	FUNCTIONAL LOWER URINARY TRACT VOIDING OUTCOMES AFTER CYSTECTOMY AND ORTHOTOPIC NEOBLADDER. <i>Journal of Urology</i> , 2000, 163, 56-59.	0.2	48